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INTRODUCTION
N-of-1 trials or individualised medication
effectiveness tests (IMETs) are an innovative patient-
centred approach to drug management. They are
within-patient, randomised, double-blind, placebo-
controlled crossover comparisons of a drug with
another drug or a placebo, designed to remove any
placebo effect in deciding the best of two
therapeutic choices for an individual with a chronic
disease. Patients are actively involved in: accepting
a double-blind process, keeping a diary of
symptoms, and afterwards discussing the results
with their doctor, when a decision is made about
future management.
The widespread use of n-of-1 trials as a clinical tool
depends to a large extent on patients’ positive
attitudes towards the process. In the US, where n-of-
1 trials have recently become available commercially,
patient post-trial questionnaires showed a high level
of acceptability.1,2 However, little has been
documented about how patients experience n-of-1
trials, although they have been performed in medicine
for over a decade.
Previous published work has been limited to small
sections describing patient experiences within
reports of n-of-1 trials research. For example, most
patients in a previous osteoarthritis n-of-1 trial viewed
the process favourably, obtaining a better
understanding of their condition, and enjoying the
discussion of their results and future treatment.3
Patients of a US n-of-1 trials service consistently
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ABSTRACT
Background
N-of-1 trials are within-patient, randomised, double-
blind, placebo-controlled cross-over comparisons of
two drugs for chronic illnesses. We have investigated
the use of these, offered to doctors as individualised
medication effectiveness tests (IMETs), as a tool to
improve drug prescribing.
Aim
To examine patient perspectives and experiences of
n-of-1 trials.
Design of study
We provided n-of-1 trials for osteoarthritis (OA),
comparing paracetamol and ibuprofen; and attention
deficit hyperactivity disorder (ADHD), comparing
dexamphetamine or methylphenidate and placebo.
Patients or their carers were surveyed before and after
the trials by questionnaire, and after the trial by semi-
structured interview with thematic analysis.
Setting
Australian community-based patients and practitioners.
Method
Forty-two patients with OA and 21 carers of patients
with ADHD, for whom the effectiveness of proposed or
existing medication was uncertain, completed the
questionnaires, and 25 patients/carers (11 with OA and
14 with ADHD) participated in semi-structured
interviews.
Results
Patients in this purposive sample were generally very
satisfied with the n-of-1 trial process. Their
participation led to increased knowledge, awareness
and understanding of their condition, their bodies’
response to it, and its management. Some of this
arose specifically from use of daily symptom diaries.
This led to a sense of empowerment and control as
well as improved individually-focused care.
Conclusions
N-of-1 trials appeared to empower these patients as a
result of both collecting information about their
responses to different treatment options, and
participating actively in subsequent therapeutic
decisions. They are a patient-centred intervention that
may improve medication management in suitable
chronic diseases.
Keywords
attention deficit hyperactivity disorder; osteoarthritis;
patient-centred care
C Jane Nikles, Alexandra M Clavarino and Chris B Del Mar
C J Nikles, MBBS, senior research fellow, Discipline of General
Practice; A M Clavarino, BA, PhD, senior research fellow,
School of Population Health, The University of Queensland
Medical School, Herston, Queensland, Australia. C B Del Mar,
FRACGP, MD, dean, Faculty of Health Science and Medicine,
Bond University, Gold Coast, Queensland, Australia.
Address for correspondence
C Jane Nikles, Centre for General Practice, The University of
Queensland Medical School, Herston, Queensland 4006,
Australia. Email: j.nikles@uq.edu.au
Submitted: 13 December 2003; Editor’s response: 01 June
2004; final acceptance: 13 September 2004.
©British Journal of General Practice 2005; 55: 175–180.
Original Papers
C J Nikles, A M Clavarino and C B Del Mar
176 British Journal of General Practice, March 2005
rated their trials as ‘extremely useful’.4 An Australian
doctor reported that the result of a single attention
deficit hyperactivity disorder (ADHD) n-of-1 trial was
well accepted by the patients’ parents5 and a
Canadian study found that ADHD n-of-1 trials were
endorsed by families, who used the results to make
treatment decisions.6 This is the first qualitative report
we are aware of that focuses entirely on patients’
experiences of n-of-1 trials.
METHOD
The Discipline of General Practice at The University of
Queensland has established and previously
described a post-and-telephone n-of-1 trial service
throughout Australia.7,8 Here we present some of the
comments of the initial patients in the osteoarthritis
(OA) n-of-1 trial comparing paracetamol and
ibuprofen7 (11 interviewees and 42 questionnaire
completers) and ADHD n-of-1 trial comparing
dexamphetamine or methylphenidate with placebo
(14 interviewees [four were children aged 12 years
and under] and 25 adult questionnaire completers).8
Community patients/caregivers were referred by
GPs or paediatricians and provided informed
consent. Patient characteristics are given in Table 1.
Many patients were already on medication, but either
the doctor or patient (or their caregiver) was uncertain
as to the effectiveness of the medication.
Data collection
Pre- and post-trial questionnaires used a series of
open-ended questions to elucidate the reasons for
participation in the n-of-1 trials, general subjective
experiences of participation and patients’ participation
in the decision-making process after the trial. We also
conducted qualitative semi-structured interviews with
a subgroup of questionnaire responders to explore
issues raised in the questionnaires, and other relevant
issues, in more detail. From June to September 2001
we interviewed patients either face to face (n = 11) or
by telephone (n = 14) until no new data were obtained.
Interviewees in the sample who did not complete the
n-of-1 trial were asked about reasons for withdrawal
(OA, n = 2; ADHD, n = 2). All interviews were recorded
and transcribed verbatim.
Sample
In accordance with well accepted qualitative
techniques the interview sample was purposively
selected from different categories; for example: male/
female; responder/non-responder/non-completer;
metropolitan/provincial/rural; caregiver/child, to
provide as broad a range of data as possible,
highlighting the variety of perspectives and
experiences. Most interviewees belonged to several of
these categories simultaneously. The sample did not
attempt to be representative as this was a qualitative
study describing patients’ experiences. 
Data analysis
Data from both sources (interviews and
questionnaires) were treated as text, combined and
analysed. A thematic coding scheme was developed
on the basis of the analysis of pilot interviews. All data
were coded by two researchers and any differences
resolved by consensus. All reasonable steps have
been taken to maintain patient confidentiality. 
RESULTS
There were three groups of patients: children with
ADHD, the carers of these children, and older adults
with OA. Only children over 12 years completed
questionnaires. 
Reasons for participation 
Participants commenced n-of-1 trials after hearing
about them either from their doctor (the majority),
directly from the media, or from a chronic disease
support group. The ability of the trials to give
ADHD Children 
Patients OA carers with ADHD Total
Age range (years) 40–80 26–58 7–15 7–80
Female (%) 25 (59) 23 (92) 5 (24) 53 (60)
Male (%) 17 (40) 2 (8) 16 (76) 35 (40)
Non-English speaking 6 (14) - - 6 (7)
background (%)
Highest educational level 25 (59) 16 (38) - 41 (47)
grade 10a or less (%)
Employed (%) 11 (26) 12 (48) - 23 (26)
Married (%) 28 (67) 14 (56) - 42 (48)
Prior treatment for depressive - 5 (20) - -
disorder (%)
Total 42 25 21 88
ADHD = attention deficit hyperactivity disorder. OA = osteoarthritis. aCompulsory education.
Table 1. Summary of characteristics of questionnaire
responders.
How this fits in
Although n-of-1 trials have been performed in
medicine for over a decade, little has been
documented about how patients experience them.
This is the first qualitative report we are aware of
focusing entirely on patients’ experiences of these
trials. N-of-1 trials appeared to empower patients as
a result of both collecting information about their
responses to different treatment options, enabling
them to participate actively in subsequent therapeutic
decisions. They are a patient-centred intervention that
may improve medication management.
Original Papers
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individual information appealed to many patients. 
For a number of patients, getting the correct
medication was of considerable importance: 
‘[I would like to] get the right medication which is
right for me!’ (Female, OA, aged 59 years.) 
‘I will look back and see if I need the tablets.’
(Male, ADHD, aged 12 years.)
Several also participated to learn more about the
disease, and particularly pain control: 
‘I hope to be able to gain valuable knowledge and
experience to help our family and child through
the torment of ADHD.’ (Female carer, ADHD,
aged 26 years.) 
For the majority of patients with OA, the
predominant expectation was that symptoms,
particularly pain, would improve. They wanted to: 
‘... learn more about the effects of arthritis and
relief of pain. To learn about what medication
would help me.’ (Female, OA, aged 73 years.)
‘... be able to live a little more pain free, also to
understand my body and pain. To have better
control.’ (Male, OA, aged 75 years.) 
Functional outcomes were important to some OA
patients — clearly, the OA had great impact on their
lives, and the ability to work and lead a normal life
was important. 
Like the OA patients, the majority of caregivers of
children with ADHD wanted to know whether the test
drug was effective and whether their child really
needed it. Gaining knowledge about ADHD was
another important reason to do the n-of-1 trial. For
rural and remote parents, the ADHD n-of-1 trial
delivered by post and telephone provided an
opportunity for them to actively participate in their
child’s management. 
‘We live 250 km from [regional Australian city].
The test gave us the chance to be doing
something. It’s not just doctor oriented, it’s
something we can do, we can see and observe.’
(Female carer, ADHD, aged 31 years.)
Older children understood clearly why they were
doing the n-of-1 trials — to find out whether they
could cease the medication. 
‘[After doing IMET] I’ll get of my
dex[amphetamine].’ (Male, ADHD, aged 15 years.)
Benefits of participation in the n-of-1 trials 
For both OA and ADHD there were common themes
relating to benefits of the trials. 
Many OA patients in particular had a long history of
searching for effective medications, and the n-of-1
trial helped to clarify which medication worked for
them:
‘[What] I’ve found is one that works and one that
doesn’t.’ (Female, OA, aged 58 years.)
‘It proves that taking paracetamol regular[ly] is
better than anti-inflammatory drugs.’ (Female,
OA, aged 75 years.) 
There was an enhanced awareness and
understanding of their condition, which was not
obtained from usual patient–doctor interaction:
‘When I feel the start of the pain I take a pill. Nip
it in the bud. The only way to do that is to think
about it in the morning. Once I get control it goes
out of my mind.’ (Male, OA, aged 60 years.)
‘Yes! I am more knowledgeable about ADHD. Just
my reading all the relevant info! … We received a
more thorough evaluation of A. One which we
would not have received if she was not placed on
the trial.’ (Female carer, ADHD, aged 35 years.)
N-of-1 trials increased knowledge about proper
use of the medication:
‘I tried [ibuprofen] once years and years ago and I
got a sore stomach. I was taking them for pain but
I was taking them without a feed, that’s why this
time I make sure I take a sandwich.’ (Male, OA,
aged 60 years, responder to NSAIDs for stiffness.)
Several patients commented on the extra
information the results gave their doctor, including
how they responded to their medication:
‘Once the program is complete you will, and
your doctor will, know much more about you and
your condition.’ (Male, OA, aged 43 years.)
As a result of increased knowledge and awareness,
patients and parents felt a greater sense of control
and were more able to help themselves or their child:
‘I feel more in control of treatment.’ (Male carer,
ADHD, aged 40 years.)
They felt that they were treated more individually and
more thoroughly during the trial than they were used to: 
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‘That’s what I liked about it; it doesn’t matter if
you’re in a class of people, the teacher isn’t
talking to you directly. I like this one-on-one. You
do better.’ (Male, OA, aged 60 years.)
It is not uncommon for parents and children to be
equivocal about taking ADHD medication. Issues for
parents include public opinion against stimulant
medication, a desire for the best treatment for their
child, uncertainty about whether they had made the
right decision to medicate their child, and concerns
about the long-term effects of having their child on
stimulants. The key issue for children on stimulant
medication is their desire to cease it. N-of-1 trials
showed whether or not the ADHD medication was
really necessary and provided what was seen as
‘proof’ and reassurance.
‘R could see the difference between the two
medications ... he has accepted the medication
and his test results ... he accepted his condition
because of the test. It proved a point — that we
were heading down the right track ... It proved I
was morally right … and proved how much the
dex worked ... At this stage he cannot control
himself without them.’ (Female carer, ADHD, aged
42 years.)
When the n-of-1 trial demonstrated the need for
medication, children with ADHD (responders)
volunteered that they could accept their condition
better, and some parents also felt reassured about
their parenting skills:
‘The trial showed that it’s not my fault the way he
is. It has made me feel better about my parenting
skills.’ (Female carer, ADHD, aged 42 years.)
Removal of some of the stigma and scepticism
regarding drug treatment was important: 
‘I am now not as sceptic[al] about taking drugs.’
(Female carer, ADHD, aged 35 years.)
However, the n-of-1 trials were not suitable for all
patients. Most OA withdrawals (n = 10) occurred in the
first treatment period, the majority because of side
effects and ineffectiveness of tablets (Table 2).
Relatively few ADHD withdrawals (n = 4) occurred.
These were mostly in the second treatment pair and
they withdrew due to deterioration of symptoms on
placebo (Table 3). The protocol now allows those
experiencing deterioration to switch to the next
treatment period after a couple of days, rather than
waiting a week.
The results and post-trial management
decision-making 
Different perspectives towards their reports are
demonstrated by responders and non-responders.
Responders commented on the differences between
the medications:
‘It gave me a proper indication of what the pills
were actually doing and how I felt when I was
taking them. It gave Dr L an indication of which
pill was really working. [The graphs] really pointed
it out.’ (Male, OA, aged 43 years.)
‘[With the] charts — the teacher’s and mine —
[there was a] difference between placebo and
active ... [we] could see differences in behaviour.’
(Female ADHD carer, aged 34 years.)
Some non-responders felt that because they did
not have a response, the n-of-1 trial had not helped.
However, most of them came to the conclusion that
the test medication simply did not work for them and
another approach needed to be sought:
‘I obtained what I thought I would achieve,
[that is, finding out whether] arthritis
medications [for example, ibuprofen] [could]
help me or not, but quite obviously I am just as
well on painkiller[s] when necessary.’ (Female,
OA, aged 70 years.) 
Number of patients
OA n-of-1 trial
Timing of withdrawal
In first treatment period 10
In second treatment period 4
In third treatment period 0
Reason for withdrawal
Side effects 6 (1 on placebo)
Tablets not helping 4
Could not cope 1
Ill health 1
Too many tablets 1
Serious adverse event 1
ADHD n-of-1 trial
Timing of withdrawal
In first treatment period 1
In second treatment period 2
In third treatment period 1
Reason for withdrawal
Deterioration on placebo 2
Side effects 1
No teacher input 1
ADHD = attention deficit hyperactivity disorder. OA =
osteoarthritis.
Table 2. Timing of and reasons for
withdrawal from OA and ADHD n-of-1
trials.
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In many cases, ADHD non-responders and their
parents were pleased that stimulant medication
could be ceased:
‘W thought she was special because she was
doing the [n-of-1 trial. The trial] proved that Mum
was right … and W is happy not to be on tablets.’
(Female ADHD carer, aged 42 years, mother of
non-responder.)
For both OA and ADHD, a continuum of
responsibility for the post-test management decision
was observed, ranging from those who believed that
the final decision about medication was up to them,
to those who wanted the doctor to make the decision: 
‘I had a lot of say in the final decision, and the
doctor and I had a talk together and we decided
together what would be the best way to go.’
(Female, OA, aged 58 years.)
For ADHD, there was a complex interplay of input
from caregivers, teachers, children and doctors: 
‘We were a bit nervous about taking control and
making the decision. I feel relieved now — we’re
confident she is on the right medication.’
(Female, ADHD carer, aged 31 years.)
DISCUSSION
Summary of main findings 
In this varied group of patients, n-of-1 trials were well
accepted and highly beneficial. Patients in this
sample were generally very satisfied with the n-of-1
trial process. Their participation led to increased
knowledge, awareness and understanding of their
condition; their bodies’ response to it, and its
management. This led to a sense of empowerment
and control as well as increased individually-focused
care.
Strengths and the limitations of this study 
This study provides more depth than the existing
literature on patients’ experiences of the n-of-1 trial
process. As n-of-1 trials are becoming more
commonly used, patients’ experiences and feedback
can be used to improve the way in which they are
delivered, and could make a valuable contribution
towards both the frequency of use and the usefulness
of n-of-1 trials in clinical practice.
There may be some positive bias in the interview
data (participants may have been less likely to
mention negative experiences) because of the
presence of one of the researchers; however, the
interviewer did not have any patient contact during
the actual trials. As all participants had ongoing
contact with the research team, it is unlikely that the
type of interview (face-to-face or by telephone) would
have greatly biased the data obtained. Additionally,
more patients who completed the n-of-1 trials than
withdrew were willing to complete both pre- and
post-trial questionnaires, and the interview sample
was drawn from this group. No patients were
unwilling to be interviewed.
This is a qualitative study and these types of
studies are not commonly conducted in general
practice research. The actual numbers (63 patients in
the group; 25 interviews) are not as important as in a
quantitative study, which usually aims to be
representative of a particular population. Patients
were invited to participate in the interviews because
they were considered to be ‘information rich’; they
had particular experiences or perspectives that were
of interest to this study.
Interviews continued with additional responders
until the data reached saturation (no new information
was obtained). This was achieved with 25 patients, so
there was no need to interview all 63. In other words,
as we were interested in studying the breadth of
issues, qualitative studies were best suited: had
representativeness been our main interest, then
quantitative methods would have been better. We are
not attempting to apply the results from this sample
to the whole population.
Our withdrawal rates (14/42 [33%] for OA and 4/21
[19%] for ADHD) are comparable with or better than
withdrawal rates of other Australian n-of-1 studies
(40% and 37%).3,9 Withdrawals were mostly due to
factors other than the n-of-1 trial process itself.
Withdrawals from the OA n-of-1 trial were mainly
related to factors such as drug side effects or
ineffectiveness (n = 11), and two of the ADHD
withdrawals were due to side effects or lack of
teacher input. However, the remaining two ADHD
withdrawals occurred due to worsening behaviour on
placebo, a design issue we subsequently addressed,
with a noticeable reduction in withdrawal rates (CJ
Nikles, unpublished data, 2005).
The withdrawal rates can be thought of as a general
measure of the compliance (‘adherence’) of the
patients, and adherence is not as good as many
clinicians believe.10 Non-adherence rates of around
50% have been reported for several common chronic
diseases.11,12–14 This is a normal phenomenon of clinical
treatment. 
Comparison with existing literature
The themes identified in this study are consistent
with the existing literature. For example, previous
work3–6 has reported favourable patient feedback and
has documented the benefits of participating in n-of-
1 trials. Feedback includes patients and carers
Original Papers
delivered by a dedicated service may one day make
a large contribution to changing the way we practice
clinically.
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obtaining a better understanding of the condition,
and benefiting from discussion of their results and
future treatment. Patients found n-of-1 trials
extremely valuable and used the results to make
treatment decisions. 
Patients appear to benefit from participation in
such trials because the process provides an insight
into their illness and provides a basis for discussion
with their medical practitioner that is not commonly
available in routine clinical practice.
The implications for clinical practice
When patients assume more responsibility for their
own health care, heath outcomes improve;15–18 this is
particularly true for prescription drugs.19 When
healthcare providers communicate with their patients
about their condition, provide them with information
and encourage them to participate in decision-
making, patients can become more active in their
medication management. N-of-1 trials provide a
structured way of increasing this participation. Being
patient-focused, n-of-1 trials can also be a useful and
convenient tool that allows providers to tailor
treatment to the individual.
Genetic variation (or polymorphism) may be an
important factor underlying inter-individual variation in
response to certain drugs. For example, genetic
defects in the dopamine transporter gene might
contribute to some forms of ADHD, explaining why
some individuals may respond to psychostimulants,
which interact with the dopamine, serotonin and
noradrenaline transporters.
Pharmacogenetics may play a future role in
predicting response to certain medications, in which
case n-of-1 trials would not be necessary. Until then,
the increasing burden of chronic illness, the rising
costs of health care (including drugs), and the
growing emphasis on patient-centred care provide a
context in which n-of-1 trials could have an important
place in the management of certain chronic
conditions. N-of-1 trials have the potential to lessen
the impact and burden of chronic disease by
improving health outcomes via targeted prescribing
and wiser self-medication.
We are not advocating the use of n-of-1 trials for all
patients in symptomatic areas of clinical medicine —
only for those where there is doubt about the
benefit:harm ratio of a particular drug, and a suitable
n-of-1 trial exists for that drug, condition and set of
patient characteristics. Currently, empirical informal
testing (‘trial of treatment’) is common in clinical
practice, but this tends to over estimate benefits of
particular therapies due to the placebo effect, the
patient’s desire to please the doctor, the
expectations or beliefs of both patient and doctor,
and the natural history of the condition. N-of-1 trials
